- How should patients be monitored over time for possible metabolic and morphologic abnormalities seemingly associated with antiretroviral therapy?
- As issues such as antiretroviral drug burden appear to be resolving themselves (eg, once-daily dosing), what regimens are best used as initial HIV therapy?
- Unexpected, contradictory antiretroviral resistance test results are common; how should clinicians manage these problems?
- What should clinicians do to diagnose and manage HIV coinfection with HBV and/or HCV?
These are some of the important questions asked, answered, and debated by HIV/AIDS thought-leaders from throughout the United States who attended the IAPAC Sessions 2002, which was hosted May 16-17, 2002, by the International Association of Physicians in AIDS Care (IAPAC).
The IAPAC Sessions 2002, which were chaired by longtime IAPAC member Renslow Sherer, focused on the practical arena of HIV management. Invited faculty, delegates and observers -- the majority IAPAC members -- addressed four areas of clinical uncertainty: metabolic/morphologic complications associated with antiretroviral therapy; utilization/sequencing of antiretroviral drugs; antiretroviral drug resistance testing in HIV clinical management; and HIV and Hepatitis B/C co-morbidity and treatment.
Faculty for the IAPAC Sessions 2002 included Maurizio Bonacini (University of Southern California); Richard Haubrich (University of California, San Diego); Diane Havlir (University of California, San Diego); David Katzenstein (Stanford University School of Medicine); Daniel Kuritzkes (University of Colorado Health Science Center); Barbara McGovern (New England Medical Center); Kathleen Mulligan (University of California, San Francisco); Stuart Ray (Johns Hopkins University School of Medicine); Renslow Sherer (Rush Medical College); Kimberly Smith (Rush-Presbyterian-St. Luke's Medical Center); Pablo Tebas (Washington University School of Medicine); and Christine Wanke (Tufts University School of Medicine).
According to IAPAC President José M. Zuniga, IAPAC plans to host the IAPAC Sessions next year in France, South Africa, and the United States -- with special emphasis on debates relevant to the respective geographical regions.
Faculty member Richard Haubrich and IAPAC Sessions 2002 Chair Renslow Sherer share a light moment between morning and afternoon sessions May 17, 2002.
David Katzenstein delivers a presentation on the limitations of antiretroviral drug resistance testing in HIV clinical management.
Olga Wildfeuer, a New York delegate, listens to a discussion about HIV-HCV co-morbidity led by faculty member Maurizio Bonatini.
Carol Harris, an IAPAC Trustee and a New York delegate, raises a question regarding PI-sparing regimens during a session on sequencing of antiretroviral therapy.
(Clockwise from top left) Irene Maina and Alawode Oladele, both delegates from Georgia; and Drew Kovach, a Hawaiian delegate.
Pablo Tebas dissects data regarding metabolic abnormalities encountered in some patients on HAART.
Washington, DC, delegate Franco Lori questions data presented on once-daily dosing of HIV medications.
Kimberly Smith enjoys a running joke with her co-presenter about their "opposing" views regarding PI-containing versus PI-sparing regimens.
Kathleen Mulligan reiterates a point about morphologic complications associated with antiretroviral drug therapy.
Stuart Ray (forefront) and Maurizio Bonacini listen to a presentation by Barbara McGovern on treatment of HIV-HCV coinfection.
David Wheeler, a Virginia delegate, volunteers his clinical experience using anti-retroviral drug resistance testing.
The IAPAC Sessions 2002 were made possible through unrestricted educational grants from Abbott Laboratories; Bristol-Myers Squibb-Virology; Gilead Sciences; GlaxoSmithKline; Ortho Biotech; Roche Pharmaceuticals/Trimeris; Schering-Plough; and Tibotec-Virco.
Back to the July 2002 issue of IAPAC Monthly.